INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 32 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $5,420,332,000 | +3.0% | 8,362,000 | -5.4% | 0.01% | -20.0% |
Q4 2020 | $5,261,461,000 | -4.9% | 8,837,000 | +9.8% | 0.01% | +25.0% |
Q3 2020 | $5,532,883,000 | +259.9% | 8,049,000 | +275.6% | 0.01% | +166.7% |
Q2 2020 | $1,537,388,000 | -15.7% | 2,143,000 | 0.0% | 0.00% | -25.0% |
Q1 2020 | $1,823,243,000 | +54.8% | 2,143,000 | +140.8% | 0.00% | +100.0% |
Q4 2019 | $1,177,568,000 | -36.9% | 890,000 | -57.2% | 0.00% | -33.3% |
Q3 2019 | $1,867,602,000 | +7.1% | 2,078,000 | +17.9% | 0.00% | 0.0% |
Q2 2019 | $1,744,524,000 | – | 1,763,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
HIGHBRIDGE CAPITAL MANAGEMENT LLC | 55,943,000 | $39,071,000 | 2.11% |
PenderFund Capital Management Ltd. | 5,000,000 | $4,719,000 | 1.31% |
Opti Capital Management, LP | 13,246,000 | $9,340,000 | 1.14% |
Context Partners Fund, L.P. | 7,485,000 | $5,145,000 | 1.12% |
Context Capital Management, LLC | 7,485,000 | $5,145,000 | 1.12% |
Soros Fund Management | 19,552,000 | $13,548,000 | 0.33% |
ADVENT CAPITAL MANAGEMENT /DE/ | 18,604,000 | $12,963,000 | 0.29% |
Senvest Management, LLC | 5,000,000 | $3,465,000 | 0.20% |
CSS LLC/IL | 2,825,000 | $1,957,000 | 0.09% |
GABELLI & Co INVESTMENT ADVISERS, INC. | 350,000 | $243,000 | 0.04% |